JHMD - ETF AI Analysis

Top Page

John Hancock Multifactor Developed International ETF (JHMD)

Rating:65Neutral

Price Target:―

The overall rating of the John Hancock Multifactor Developed International ETF (JHMD) suggests it is a moderately strong investment option, driven by holdings like Novartis AG and ASML Holding NV. Novartis contributes positively with its robust profitability, stable balance sheet, and growth in key products, while ASML adds strength through its solid revenue and profit growth despite a high valuation. However, weaker holdings like BASF SE, which faces declining revenues and low profit margins, slightly hold back the fund’s overall rating. The ETF’s diversified holdings mitigate risks, though concentration in specific sectors or regions could be a factor to monitor.

Positive Factors

Strong Geographic Diversification

The ETF invests across multiple countries, including Japan, the UK, and Germany, reducing reliance on any single economy.

Healthy Top Holdings Performance

Several top holdings, such as ASML Holding NV and Banco Bilbao Vizcaya Argentaria, have shown strong year-to-date gains, supporting the fund's overall performance.

Reasonable Expense Ratio

The ETF's expense ratio of 0.39% is competitive, making it a cost-effective option for international exposure.

Negative Factors

Sector Over-Concentration

The fund has significant exposure to the Financial and Industrials sectors, which may increase vulnerability to sector-specific downturns.

Mixed Holdings Performance

Some top holdings, such as BASF SE and Deutsche Telekom, have delivered weaker year-to-date returns, potentially dragging on overall performance.

Limited U.S. Exposure

With only 4.4% allocated to U.S. companies, the ETF may miss out on opportunities in the world's largest economy.

JHMD vs. SPDR S&P 500 ETF (SPY)

AUM840.32M

RegionDeveloped Markets

Expense Ratio0.39%

Beta0.66

IssuerJohn Hancock

Inception DateDec 15, 2016

Dividend Yield2.81%

Asset ClassEquity

Index TrackedJohn Hancock Dimensional Developed International Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume70,077

30 Day Avg. Volume61,915

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

44.47

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering590

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

JHMD Summary

The John Hancock Multifactor Developed International ETF (JHMD) is an investment fund that focuses on companies in developed international markets, such as Japan, the UK, and Germany. It includes a mix of large, mid, and small-sized companies across various industries like financials, healthcare, and technology. Some well-known companies in this ETF are Novartis and Nestlé. Investors might consider JHMD for diversification, as it provides exposure to stable economies outside the U.S. However, new investors should be aware that the ETF’s performance can be affected by global economic conditions, which may cause its value to fluctuate.

How much will it cost me?The John Hancock Multifactor Developed International ETF (JHMD) has an expense ratio of 0.39%, which means you’ll pay $3.90 per year for every $1,000 invested. This cost is slightly higher than average for passively managed ETFs because it uses a multifactor strategy to optimize risk and reward across developed international markets.

What would affect this ETF?Positive drivers for JHMD include potential economic growth in developed international markets outside North America, which could boost the performance of its top holdings like Vinci SA and Novartis AG. However, negative factors such as rising interest rates or economic slowdowns in Europe could impact sectors like Financials and Industrials, which make up a significant portion of the ETF's exposure.

JHMD Top 10 Holdings

The John Hancock Multifactor Developed International ETF (JHMD) leans heavily on financials and industrials, which together form the backbone of its sector exposure. Banco Bilbao Vizcaya Argentaria (BBVA) and HSBC are rising stars, benefiting from strong financial performance and attractive valuations. Meanwhile, healthcare names like Roche and AstraZeneca are steady contributors, with robust pipelines and strategic growth. However, industrial giant Vinci and consumer staple Nestlé are lagging, with recent performance underwhelming. With its focus on developed markets outside North America, JHMD offers a balanced yet slightly concentrated play on international economic resilience.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
0NQM	Vinci SA	1.68%	$14.12M	€68.69B	24.47%	76 Outperform
NOVN	Novartis AG	1.46%	$12.32M	CHF200.41B	13.53%	80 Outperform
SHEL	Shell (UK)	1.28%	$10.76M	£158.50B	9.00%	74 Outperform
ASML	ASML Holding NV	1.28%	$10.76M	€347.34B	44.38%	76 Outperform
BBVA	Banco Bilbao Vizcaya Argentaria	0.98%	$8.25M	€106.93B	106.11%	77 Outperform
BAS	BASF SE	0.90%	$7.59M	€39.82B	5.98%	49 Neutral
HSBA	HSBC Holdings	0.83%	$7.03M	£182.81B	45.43%	79 Outperform
AZN	AstraZeneca	0.80%	$6.77M	£219.33B	34.33%	78 Outperform
ROG	Roche Holding AG	0.80%	$6.71M	CHF250.44B	37.22%	73 Outperform
NESN	Nestlé SA	0.78%	$6.55M	CHF201.13B	13.34%	71 Outperform

JHMD Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

40.20

Positive

100DMA

39.61

Positive

200DMA

37.61

Positive

Market Momentum

MACD

-0.05

Positive

RSI

55.63

Neutral

STOCH

54.18

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JHMD, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 40.27, equal to the 50-day MA of 40.20, and equal to the 200-day MA of 37.61, indicating a bullish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 55.63 is Neutral, neither overbought nor oversold. The STOCH value of 54.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JHMD.

JHMD Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
JHMD	―	―	$840.32M	0.39%	―
QEFA	―	―	$967.04M	0.30%	―
GSID	―	―	$909.13M	0.20%	―
IQDG	―	―	$713.44M	0.42%	―
DMXF	―	―	$641.90M	0.12%	―
DWM	―	―	$603.69M	0.48%	―

Performance Comparison

JHMD

John Hancock Multifactor Developed International ETF

40.67

8.22

25.33%

QEFA

SPDR MSCI EAFE StrategicFactors ETF

―

GSID

Goldman Sachs MarketBeta International Equity ETF

―

IQDG

WisdomTree International Quality Dividend Growth Fund

―

DMXF

iShares ESG Advanced MSCI EAFE ETF

―

DWM

WisdomTree International Equity Fund

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents